SUPPLEMENT

The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach


ABSTRACT

The Massachusetts General Hospital Neuroradiology Division employed an experience and evidence based approach to develop a neuroimaging algorithm to best select patients with severe ischemic strokes caused by anterior circulation occlusions (ACOs) for intravenous tissue plasminogen activator and endovascular treatment. Methods found to be of value included the National Institutes of Health Stroke Scale (NIHSS), non-contrast CT, CT angiography (CTA) and diffusion MRI. Perfusion imaging by CT and MRI were found to be unnecessary for safe and effective triage of patients with severe ACOs. An algorithm was adopted that includes: non-contrast CT to identify hemorrhage and large hypodensity followed by CTA to identify the ACO; diffusion MRI to estimate the core infarct; and NIHSS in conjunction with diffusion data to estimate the clinical penumbra.

INTRODUCTION

The purpose was to use an experience and evidence based approach to develop the neuroimaging algorithm that best improves outcomes in patients with severe ischemic strokes caused by anterior circulation occlusions (ACOs). Patients with these strokes account for the majority of individual, family, and societal costs due to stroke, and they are treatable with intravenous (IV) tissue plasminogen activator (tPA) or/and intra-arterial therapy (IAT). Critically evaluated was the capability of each specific method to provide reliable information on three key components of stroke physiology: (1) site of arterial occlusion; (2) extent of irreversibly injured tissue (‘infarct core’); and (3) the size of the ischemic penumbra (figure 1). Although varying definitions of the ischemic penumbra exist, the penumbra is defined herein as severely hypoperfused brain tissue that may eventually be recruited into the infarct core, if not reperfused quickly enough.1

METHODOLOGY

The critical physiological information in the acute stroke patient with severe symptoms is shown in figure 1, which is a representation of a patient with a proximal right middle cerebral artery occlusion. Individual neuroradiology and neurology faculty from the Massachusetts General Hospital (MGH) presented the best evidence from the literature and clinical experience on the value of each method. Expert opinions were presented for the National Institutes of Health Stroke Scale (NIHSS), non-contrast CT (NCCT), CT angiography (CTA), CTA source images (CTA-SI), diffusion MRI, CT perfusion (CTP), and MRI perfusion (MRP). Faculty and fellows who did not present heard the evidence, met to weigh the evidence and make recommendations. Each modality was assessed on two different sets of criteria shown in tables 1 and 2. The basic practical question was: ‘Is the modality valuable for patient care and can we obtain it in an acute setting?’ In addition to traditional metrics such as sensitivity and specificity, the following factors were factored into the assessments:

- Workflow. Place of the imaging test in the workflow and does it negatively or positively affect the workflow when an acute stroke patient arrives in the emergency department.
- Repeatability. The values measured by the imaging test are not affected by extraneous parameters and repeated invocations of the test would result in the same conclusions.
- Reliability. Measured values reflect the purported physiologic parameter about the patient condition.
- Clinical efficacy. The imaging test improves patient outcomes.

ISCHEMIC STROKE THERAPY

Intravenous tissue plasminogen activator

Intravenously administered tPA is a proven effective treatment for ischemic stroke.2 The primary indicators for its administration are an elapsed time since onset of 4.5 h or less and an absence of hemorrhage or large hypodensity on imaging, usually NCCT.

Intra-arterial therapy

The target of IAT is a proximal artery occlusion. The focus here is on major ACOs which account for approximately 90% of all such occlusions.3 In patients with blockages of the intracranial internal carotid artery (ICA) or middle cerebral artery stem (M1 segment), two recent studies have demonstrated the critical role of infarct volume in determining long term functional outcome (figure 2).4 5
When patients have large final infarcts, there is a high likelihood of significant disability or death. It follows then that patients presenting with extensive infarction (ie, >70–100 ml) before treatment will have little chance for a good IAT response. Moreover, studies have shown that the risk of reperfusion hemorrhage increases with pretreatment infarct size, and is very high (~15%) when infarcts are larger than 100 ml. Therefore, risk outweighs benefit in this subset of patients. Numerous studies have confirmed the importance of core infarct size in predicting IAT outcomes. The decision to proceed to IAT therefore critically depends on the size of the infarct core at the time of treatment, and the primary role of imaging after identification of a treatable occlusion is to reliably define core infarct size accurately and precisely.

**Figure 1** Measurements of physiological components of middle cerebral artery (MCA) occlusion. Depicted is a representation of a right MCA occlusion with a growing infarct core coupled to a shrinking penumbra at a rate determined by collateral flow. The value of each method used to measure each component of stroke physiology is shown, as judged according to criteria stated in the methodology and in tables 1 and 2. CTA, CT angiography; CTA-SI, CT angiography-source images; CTP, CT perfusion; DWI, diffusion weighted imaging; NIHSS, National Institutes of Health Stroke Scale.

**Figure 2** Relationship of final infarct size to clinical outcomes in patients with major anterior circulation occlusions (ACO) treated endovascularly. The bar graphs depict the proportion of good outcomes defined as a modified Rankin Scale score of 0–2 at 3 months (blue bars) by final infarct volume strata. The data are from 107 patients with ACO. The figure was derived from Yoo et al.

### Table 1 Massachusetts General Hospital experience and practice based criteria

<table>
<thead>
<tr>
<th>Level</th>
<th>Nearly always valuable in patient care, and successfully obtainable in the vast majority of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 2</td>
<td>May be valuable in patient care, and is successfully obtainable in most patients</td>
</tr>
<tr>
<td>Level 3</td>
<td>Valuable for research purposes and may or may not help in the management of the patient</td>
</tr>
</tbody>
</table>

### Assessment of Methods

**National Institutes of Health Stroke Scale**

The NIHSS is a Level 1/Class I test in the assessment of the acute stroke patient. It helps to quickly determine if the patient is having a stroke and gives an indication of the severity of the stroke. It provides a clinically relevant estimate of the size of the ischemic tissue at risk but cannot differentiate the core from the penumbra.

**Non-contrast CT**

NCCT is a Level 1/Class I test for excluding intracranial hemorrhage and mass lesions. Because of the low sensitivity, NCCT was scored Level 2/Class IIa to detect the infarct core volume during the first few hours after stroke onset. The place of NCCT in the workflow and the order of imaging modalities were also considered and it was agreed that NCCT should be the first test in the evaluation of acute stroke. There are exceptions—for example, MRI could be undertaken as the first imaging study in patients with poor renal function who cannot get CTA, young patients presenting with acute stroke, or patients more likely to have a non-ischemic etiology, such as a mass, seizure, or migraines as the cause of their presenting symptoms.

**CT angiography**

CTA is a Level 1/Class I test for the rapid assessment of large vessel occlusion. It may also be effective for detection of medium and small vessel occlusions, even though they can take longer to find. There was no concern regarding repeatability, reliability, clinical efficacy, or overall utility of CTA. It was agreed that CTA should be performed immediately after the NCCT scan, when feasible.

**CT angiography source images**

CTA-SI have been suggested as a surrogate for the infarct core. Some older studies suggested that CTA-SI can image ischemic core. However, tissue density in CTA-SI is heavily dependent on the scan timing, cardiac output, the rate of injection, and the osmolality of the contrast media, among other parameters. For these reasons, questions were raised about the

### Table 2 Evidence based classification of recommendations

<table>
<thead>
<tr>
<th>Class I</th>
<th>An imaging modality for which there is evidence for and/or general agreement that it is beneficial, useful, and effective in the management of acute stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II</td>
<td>An imaging modality for which there is conflicting evidence and/or divergence of opinion about the usefulness/efficacy in the management of acute stroke</td>
</tr>
<tr>
<td>Class IIa</td>
<td>Weight of evidence or opinion is in favor of the usefulness or efficacy of this imaging modality</td>
</tr>
<tr>
<td>Class IIb</td>
<td>The usefulness or efficacy is less well established by the evidence or expert opinion</td>
</tr>
<tr>
<td>Class III</td>
<td>An imaging test for which there is evidence and/or general agreement that it is not useful or effective, and in some cases may be harmful, in the management of acute stroke patients</td>
</tr>
</tbody>
</table>
repeatability and reliability of CTA-SI in measuring tissue perfusion. Overall, CTA-SI was judged to be a Level 2/Class III examination in eliciting the core of an ischemic infarct.

**Diffusion MRI**

Diffusion MRI is a Level 1/Class I test for the early detection of infarct core. Diffusion weighted imaging (DWI) is nearly 100% sensitive and specific in diagnosing acute stroke\(^\text{18–25}\) although it is not perfect in identifying the infarct core. Positron emission tomography (PET) studies have shown that some non-viable tissue occasionally may not demonstrate restricted diffusion\(^\text{26,27}\). Also, DWI abnormalities are sometimes reversible.\(^\text{28–33}\) However, reversal of a DWI abnormality is unusual.\(^\text{34–7}\) When DWI reversal does occur, it usually involves only a small part of the lesion.\(^\text{35}\) Also, most of the time, the apparent DWI reversal is actually a pseudo-reversal, in that the tissue involved proceeds to infarction anyway.\(^\text{35–7}\)

**Perfusion imaging**

Brain perfusion imaging provides information on cerebral hemodynamics imbedded in parameters such as cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT). Perfusion imaging may provide many types of important information in the care of acute stroke patients.\(^\text{36–37}\) Additionally, much research has been devoted to demonstrating that perfusion imaging can identify the core and penumbra, and that perfusion imaging is useful for identifying patients with major ACOs that are suitable for interventional therapy.\(^\text{2,38–39}\) However, evidence based reviews have questioned this.\(^\text{2,40–41}\)

**Perfusion imaging: theoretical considerations**

Perfusion imaging studies the hemodynamic status of the brain at one instant in time, and there is no instantaneous hemodynamic state that uniquely characterizes the infarct core. The hemodynamic response of the brain to ischemia has been characterized with respect to cerebral perfusion pressure, and perfusion parameters are summarized in figure 3 (and in more detail in the online supplementary appendix figure A1). The autoregulatory vasodilation in response to reductions in regional cerebral perfusion pressure would be expected to result in increased, rather than decreased, CBV in ischemic tissue. Indeed, CBV may be elevated more often than reduced in the infarct core.\(^\text{42}\) More recent proposals have suggested that regions of sufficiently reduced CBF may be labeled as infarct core. This approach has greater pathophysiologic validity in that CBF reflects the rate of delivery of oxygen and glucose to brain tissue, and reductions in this rate of delivery are responsible for ischemic cell death. However, neither CBF nor any other hemodynamic measurement could ever be used to identify the core. Even complete cessation of blood flow can persist for several minutes without causing irreversible damage. Obviously, perfusion imaging demonstrates no evidence of ongoing perfusion impairment in reperfused tissue.

There are several hemodynamic measurements that are time related with no direct relationship to threats to tissue viability. For example, one of these measurements, Tmax, reflects the time that elapses between arrival of blood in an index artery and its arrival in brain tissue. A delay in the arrival of blood does not directly threaten tissue survival. MTT measures the average amount of time that blood spends in brain tissue, which is usually prolonged in underperfused brain tissue. In the setting of proximal ACO, blood must reach the tissue bed via collateral pathways whose increased circuitry would be expected to result in delayed arrival—that is, increased Tmax. Also, occlusion of a proximal artery would be expected to result in at least some reduction in distal perfusion pressure, which would cause compensatory vasodilation in some of the downstream tissue. This vasodilation by itself should result in prolongation of MTT.

Thus patients with major ACO may or may not have large regions with reduced CBF but virtually all of these patients will demonstrate large regions of MTT and Tmax elevation. Empirically, we have shown this to be the case, as demonstrated in the online supplementary appendix figure A2.\(^\text{43–44}\) In general, the existence of a large region with increased Tmax and MTT may be inferred from the existence of a proximal artery occlusion on CT or MR angiographic imaging alone.

**CT perfusion**

Several issues and concerns about CTP were raised in addition to radiation exposure. These concerns—which are related to the workflow, process of obtaining CTP maps, and the utility of the information derived from a CTP study—are summarized below.

**CTP process and workflow**

There is a lack of clear guidelines on when CTP should be performed, and how it should be interpreted. There was broad agreement that:

- Quantification of perfusion using CTP is not validated.
- There is high inter-vendor variability.
- There is high intra-vendor variability based on the software version used.
- The variability in CTP maps is as yet unquantified with respect to the variations in heart rate, blood pressure, ejection fraction, rate of infusion, osmolality of IV contrast, rotation time, and temporal resolution of the scanner.\(^\text{45}\)
- The efficacy of CTP in improving patient outcomes is unproven.

Studies performed at MGH directly comparing core volumes by DWI and CTP in patients with severe strokes with ACOs...
revealed statistically significant high correlations between the two methods. However, while there is good correlation in a population, there is a wide clinically relevant discordance between DWI and CTP derived core volumes in individual patients (see online supplementary appendix figure A3).

The above considerations led to the following guidelines on the use of CTP.

- CTP is a Level 3/Class IIb method for early estimation of the infarct core in acute stroke patients. Because CTP is unable to adequately estimate the core, it necessarily follows that it is a Level 3/Class IIb method for estimation of the penumbra.
- CTP has no proven role in selecting ACO patients for IV thrombolysis or endovascular therapy. Its roles should be limited to:
  - Research patients
  - Patients who cannot get a diffusion weighted MRI
  - Perfusion data could be used for other purposes such as hypertensive therapy. However, there are scant data on this application.

**MR perfusion**

MRP was deemed preferable to CTP because there is no radiation exposure and it has a generally superior workflow. However, the repeatability, reliability, and clinical efficacy of MRP raise similar concerns to those of CTP including:

- Quantification using MR perfusion maps is not validated.
- There is high inter-vendor variability.
- The variability of MRP maps with respect to physiologic variables (e.g., heart rate, blood pressure, ejection fraction) and scan parameters (e.g., rate of infusion, osmolality of IV contrast, rotation time, etc) is unknown.

Carroll and colleagues performed a Bland–Altman analysis of eight smokers who were imaged with MRP and H$_2$-$^{15}$O PET and concluded that “Until reproducibility is improved, MR is not suitable for reliable quantitative perfusion measurements.”

Other research assessing the reliability of MRP was also reviewed. For example, Takasawa and colleagues studied perfusion MR (deconvolution method) and PET in five patients, back to back, at a mean time interval of 16 h after stroke onset. The authors concluded that “MRP appears sufficiently reliable for clinical purposes”. However, most participants deliberating on the value of the methods thought that reliability does not override the concerns regarding high variability and low repeatability.

Overall, MRP was judged to be a Level 3/Class IIb technique in the management of acute stroke. There was broad agreement that:

- MRP has no proven role in selecting ACO patients for endovascular therapy. There is preliminary evidence that it may improve patient selection for intravenous thrombolysis but this evidence is currently insufficient to justify MRP’s clinical use in this role.
- Clinical indications for MRP may include:
  - Research patients
  - If perfusion data are deemed essential for evaluating the full clinical picture
  - When perfusion data can be used for other purposes such as hypertensive therapy, although there are few data on this.

**The clinical penumbra**

The evidence supports that the clinical penumbra, as measured by a combination of the NIHSS and the core determined by DWI, is the best indicator of a poor outcome in the absence of timely reperfusion. The PROlyse in Acute Cerebral Thromboembolism II trial demonstrated that patients with NIHSS scores <10 did not derive a clinical benefit from IA T.$^{48}$ This is due to the relatively good natural history in this subset of patients.$^{49}$ Approximately one-third of the middle cerebral artery M1 segment occlusions present with such low scores.$^{50}$ The evidence best supports the following definition of a clinically significant penumbra: (1) major anterior circulation (ICA terminus or M1) occlusion; (2) NIHSS score >10; and (3) small core infarct size (DWI lesion volume <70). Both NIHSS and DWI are Level 1/Class I tests; together it is judged to be a Level 1/Class I method to assess the clinically relevant penumbra.

**THE MGH STROKE IMAGING ALGORITHM**

Based on the conclusions of the evaluation committee on the value of each method delineated above, a new imaging algorithm was proposed and adopted. A diagram of the algorithm is shown in figure 4. Briefly, all patients presenting with a stroke syndrome receive a neurological evaluation, including the NIHSS. NCCT is performed followed by CTA. If NCCT does not demonstrate hemorrhage or large hypodensity, and the patient is within the time window, tPA is prepared while the

![Figure 4](Image)
CTA is performed, and infusion begins once it is prepared. If the patient has a distal ICA and/or proximal middle cerebral artery occlusion, he/she is moved to the MRI scanner where diffusion MRI is performed. If the DWI lesion is small (<70 ml), the patient is sent for IAT if the additional clinical and medical criteria are met. Perfusion imaging with CT or MRI may be performed if these conditions are not met, the patient cannot be scanned by MRI, or is not otherwise eligible for IAT and there is relevant clinical information that may be provided by the perfusion data.

After the algorithm was adopted, there was a significant decline in the number of perfusion CT examinations performed, as shown in the online supplementary appendix figure A4. From 40–50 CTP examinations per month in stroke patients performed during the peak years of 2005–2008, it fell to approximately 10 per month. There has been no discernible effect on patient outcomes.

Contributors: All authors contributed to the manuscript and study.

Competing interests: JMR is on the imaging committee of the DIAS trial for Lundbeck Pharmaceuticals. MHL has research support from GE Healthcare and is a consultant for Millennium Pharmaceuticals.

Provenance and peer review: Commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/


